The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.

@article{Rostaing2014ThePO,
  title={The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.},
  author={Lionel P E Rostaing and Maarten H. L. Christiaans and John M. Kovarik and Julio Pascual},
  journal={Annals of transplantation},
  year={2014},
  volume={19},
  pages={337-45}
}
BACKGROUND Pharmacokinetic data regarding a drug-drug interaction between everolimus and tacrolimus are sparse. MATERIAL AND METHODS In a pharmacokinetic substudy of the randomized ASSET trial, 46 de novo kidney transplant patients receiving very low (1.5-3 ng/mL) or low (4-7 ng/mL) tacrolimus exposure after month 3, both with everolimus and steroids, provided area under the curve (AUC) concentration profiles at day 5 and months 1, 3, and 12. RESULTS At month 12, mean values for tacrolimus… CONTINUE READING